Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer
European Urology Focus · 2025
DOI: 10.1016/j.euf.2025.05.021 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Urology Focus, 2025. Verfasst von Mykyta Kachanov und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genetic Testing, Practice Guidelines as Topic, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universität zu Köln.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Germline genetic testing (GGT) is useful for identifying prostate cancer (PCa). This study aims to evaluate the GGT criteria according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines on oncology (NCCN guidelines) for PCa, version 1.2022, for identifying PCa patients to whom GGT at a nonmetastatic stage should be offered. METHODS: Consecutive patients referred to our center were assessed using the GGT criteria from the NCCN guidelines version 1.2022. All patients received GGT for the PCa-associated genes ATM, BRCA1, BRCA2, CHEK2, TP53, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13. Detection rates of pathogenic or likely pathogenic variants (PGVs) were used to assess the criteria. Additionally, the detection rates of PGVs between different versions of the NCCN guidelines recommended GGT criteria were compared. KEY FINDINGS AND LIMITATIONS: Of 376 patients, testing was performed prior to radical prostatectomy and salvage lymphadenectomy in 346 (92.0%) and 30 (8.0%) patients, respectively. We detected 47 PGVs in 46 (12.2%) patients. Logistic regression analyses revealed high-risk PCa characteristics as a significant predictor of PGVs (odds ratio 2.19, 95% confidence interval 1.18-4.13, p = 0.01). Applying the GGT criteria outlined in the NCCN guidelines versions 2.2019 and 3.2024, PGVs were detected in 12.5% and 12.6% of the patients, respectively. Compared with the NCCN guideline version 1.2022, both the testing criteria would have missed five patients with PGVs. CONCLUSIONS AND CLINICAL IMPLICATIONS: The GGT criteria outlined in the NCCN guidelines version 1.2022 for nonmetastatic high-risk PCa patients provide a robust framework for identifying patients at a high risk of PGVs. Therefore, GGT should be offered to patients with nonmetastatic PCa in accordance with these GGT criteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
- Cologne Center for Genomics, Medical Faculty, University of Cologne, Cologne, Germany.
- Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Electronic address: budaeus@uke.de.
Förderung
- Universität zu Köln
Zitieren
APA
Kachanov, M., Volk, A. E., Falkenbach, F., Möllring, A., Hauke, J., Rading, K., Frommolt, P., Becker, K., Graefen, M., Schmutzler, R. K., Maurer, T., Hahnen, E., & Budäus, L. (2025). Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2025.05.021
Vancouver
Kachanov M, Volk AE, Falkenbach F, Möllring A, Hauke J, Rading K, et al. Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer. European Urology Focus. 2025. doi:10.1016/j.euf.2025.05.021
BibTeX
@article{Kachanov2025,
author = {Kachanov, Mykyta and Volk, Alexander E and Falkenbach, Fabian and Möllring, Anna and Hauke, Jan and Rading, Katrin and Frommolt, Peter and Becker, Kerstin and Graefen, Markus and Schmutzler, Rita K and Maurer, Tobias and Hahnen, Eric and Budäus, Lars},
title = {Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer},
journal = {European Urology Focus},
year = {2025},
doi = {10.1016/j.euf.2025.05.021}
}
EUVIMED